Table 1.
Characteristics of Study Participants
| Characteristic | N = 287 |
|---|---|
| Demographic | |
| Age, years | 47.5 (42.4–51.9) |
| Female | 102 (35.5%) |
| Black | 270 (94.1%) |
| Behavioral | |
| Injection drug usea | 123 (42.9%) |
| Alcohol usea | |
| None | 138 (48.1%) |
| Weekly | 125 (43.6%) |
| Daily | 24 (8.4%) |
| HIV-related | |
| CD4N | 282 (147–463) |
| CD4% | 22 (14–30) |
| HIV RNA | 1020 (400–32 000) |
| HIV RNA >400 copies/mL | 156 (54.6%) |
| Recent HAART usea | 134 (46.7%) |
| Hematologic | |
| Platelet count | 219 (180–259) |
| TLC | 1316 (952–1850) |
| Liver-related | |
| AST (IU/mL) | 39 (29–59) |
| ALT (IU/mL) | 31 (21–47) |
| HCV Ab positive | 269 (93.7%) |
| HCV RNA (log10 IU/mL)b | 6.55 (6.01–7.08) |
| HBsAg positive | 14 (4.9%) |
| Liver stiffness (kPa) | 7.25 (5.40–10.6) |
All values are No. (%) for dichotomous variables or median (interquartile range) for continuous variables.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CD4N, CD4+ T-cell lymphocyte count; CD4%, CD4+ T-cell lymphocyte percentage; HAART, highly active antiretroviral therapy; HBsAg, hepatitis B virus surface antigen; HCV Ab, hepatitis C virus antibody; HIV, human immunodeficiency virus; IU, international units; kPa, kilopascal; TLC, total lymphocyte count.
a In the preceding 6 months.
b HCV RNA testing available for 136 (51%) participants.